F
NVO

FolioMetrix’s Novo Nordisk NVO Stock Holding History

FolioMetrix’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$473K Buy
19,500
+11,308
+138% +$318K 0.2% 108
2015
Q1 		$219K Sell
8,192
-4,736
-37% -$109K 0.11% 137
2014
Q4 		$234K Buy
+12,928
New +$289K 0.17% 119

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

FolioMetrix's NVO Position: Q2 2015 in Review

FolioMetrix increased its Novo Nordisk (NVO) stake by 138% in Q2 2015, buying an estimated $318K and bringing the position to 19,500 shares worth $473K. The position accounts for 0.2% of the portfolio, ranked #108.

FolioMetrix first reported a position in NVO in Q4 2014 and has held it in 3 quarters since. 517 funds tracked by Wall St. Rank hold NVO as of Q2 2015.

  • FolioMetrix held 19,500 shares of Novo Nordisk worth $473K as of Q2 2015.
  • FolioMetrix bought 11,308 Novo Nordisk shares in Q2 2015, an estimated $318K.
  • Novo Nordisk made up 0.2% of FolioMetrix's portfolio in Q2 2015, its #108 holding.
  • FolioMetrix first reported a position in Novo Nordisk in Q4 2014 and has held it in 3 quarters since.
  • 517 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2015.

Based on FolioMetrix's 13F filing for Q2 2015, filed 5 Aug 2015.